Helen Torley, PRESIDENT AND CEO at HALOZYME THERAPEUTICS, INC. (HALO), sold 80,000 shares at $52.96 ($4.3M) on 2025-06-20, disclosed to the SEC on 2025-06-24.
Scheduled sale ($4.3M) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $52.96 | 20,000 | $1.1M | 24.9% |
| 2 | $52.57 | 20,000 | $1.1M | 24.7% |
| 3 | $53.11 | 4,489 | $238K | 5.6% |
| 4 | $53.11 | 4,489 | $238K | 5.6% |
| 5 | $53.91 | 15,511 | $836K | 19.6% |
| 6 | $53.91 | 15,511 |
| $836K |
| 19.6% |
| Total | $53.25 avg | 80,000 | $4.3M | 100% |
| Filing → |
| HALO | SELL | 2026-07-09 | $153K | — | Filing → |
| HALO | SELL | 2026-06-03 | $3.4M | — | Filing → |
| HALO | SELL | 2026-05-13 | $3.4M | — | Filing → |